Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
暂无分享,去创建一个
K. Rezvani | D. Marin | J. Goldman | L. Foroni | G. Gerrard | M. Bua | A. Reid | J. Apperley | Richard Szydlo | Amr Ibrahim | D. Milojkovic | Jane F. Apperley